COLORECTAL ADENOCARCINOMA
Clinical trials for COLORECTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new COLORECTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for COLORECTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Chemo-Immunotherapy combo outsmart resistant colorectal cancer?
Disease control OngoingThis phase 2 trial is testing whether adding the immunotherapy drug nivolumab (Opdivo) to standard chemotherapy (oxaliplatin, 5-fluorouracil, folinic acid) can help control or shrink a hard-to-treat type of metastatic colorectal cancer (pMMR/MSS). The study includes 80 adults who…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
Smaller cuts, faster healing? new surgery trial for colon cancer
Disease control OngoingThis study compares a newer, less invasive type of surgery (reduced-port laparoscopy) to the standard approach for people with colon or upper rectal cancer. The goal is to see if the reduced-port method is just as safe and effective, while possibly causing less pain and speeding …
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: NA • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New combo approach for Lung-Limited colorectal cancer shows promise in early trial
Disease control OngoingThis phase 2 trial studies whether combining chemotherapy with surgery to remove lung tumors works better than either treatment alone for patients with colorectal cancer that has spread only to the lungs. About 40 participants will be grouped by risk level to see if the combinati…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New combo shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis phase 2 trial is testing a combination of two drugs, cabozantinib and nivolumab, in 48 people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if the combination can shrink or stabilize tumors. All participants have a type of …
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Could vitamin D3 boost chemo for advanced colon cancer?
Disease control OngoingThis phase III trial tests whether adding high-dose vitamin D3 to standard chemotherapy and bevacizumab helps people with metastatic colorectal cancer. About 455 patients who have not had prior treatment for their advanced disease are taking part. The goal is to see if the vitami…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
New trial tests if adding chemo before and after surgery boosts survival for abdominal spread of colorectal cancer
Disease control OngoingThis study looks at whether giving chemotherapy before and after surgery (plus heated chemo inside the abdomen) helps people with colorectal cancer that has spread to the lining of the belly live longer compared to having surgery alone. About 358 adults with resectable tumors are…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Koen Rovers • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
New combo therapy aims to stop colorectal cancer from coming back
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a personalized approach for colorectal cancer patients who have a high risk of the cancer returning after surgery. Ten adults aged 18-80 with stage II (high-risk) or stage III colorectal cancer will receive standard chemotherapy plus a custom-made imm…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Second Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New drug cocktail targets Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests whether a combination of three drugs—cisplatin, nivolumab, and temozolomide—can shrink tumors in people with advanced colorectal cancer that has not responded to other treatments. The cancer must be a specific type called MMR-proficient. The trial involves 18 par…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug aims to shrink hard-to-treat GI tumors
Disease control OngoingThis study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New combo therapy targets tough colorectal cancer
Disease control TerminatedThis study tests the safety and effectiveness of combining the experimental drug AVUTOMETINIB (VS-6766) with cetuximab in people with advanced colorectal cancer that has a KRAS mutation. It is for those whose cancer worsened after prior treatments or who cannot tolerate them. The…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New cancer drug TST003 enters human trials for advanced tumors
Disease control OngoingThis early-stage study tests a new drug called TST003 in about 111 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose, check side effects, and see if the drug can shrink tumors. Participants receive TST003 th…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated May 27, 2026 12:02 UTC